File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.5009/gnl19434
- Scopus: eid_2-s2.0-85090913433
- PMID: 32457279
- WOS: WOS:000569359000018
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
Title | Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma |
---|---|
Authors | |
Keywords | Entecavir Hepatocellular carcinoma Hepatitis B core-related antigen Chronic hepatitis B |
Issue Date | 2020 |
Publisher | Gut and Liver, Editorial Office. The Journal's web site is located at http://www.gutnliver.org/ |
Citation | Gut and Liver, 2020, Epub 2020-05-29 How to Cite? |
Abstract | Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of HBcrAg in entecavir (ETV)-treated CHB patients with subsequent HCC development. We identified HCC cases diagnosed at ≥1 year after ETV initiation. CHB patients without HCC (matched for age, sex, cirrhosis status, baseline hepatitis B virus (HBV) DNA level, and ETV treatment duration) were identified as controls at an HCC:non-HCC ratio of 1:2. Serum samples were retrieved at baseline (ETV initiation) and at 3 and 5 years of ETV therapy for HBcrAg measurement (log IU/mL). In total, 180 patients (60 HCC patients matched with 120 CHB patients without HCC; median age, 56.5 years; 80.6% male; baseline HBV DNA, 5.9 log IU/mL; median follow-up, 6.8 years) were recruited. The median time from ETV initiation to HCC development was 3.2 years. HBcrAg levels were higher in HCC cases than in controls at all three time points: 5.69 log IU/mL versus 5.02 log IU/mL (p=0.025), 4.23 log IU/mL versus 3.36 log IU/mL (p=0.007), and 3.86 log IU/mL vs 3.36 log IU/mL (p=0.009), respectively. ETV led to similar rates of decline in HBcrAg from baseline to 3 years in both groups (0.34 log IU/mL/year vs 0.39 log IU/mL/year, p=0.774), although the decline from 3 to 5 years was slower in the non-HCC group (0.05 log IU/mL/year) than in the HCC group (0.09 log IU/mL/year, p=0.055). ETV time-dependently reduced HBcrAg in HCC and non-HCC patients. HBcrAg interpretation should consider the antiviral treatment duration. |
Persistent Identifier | http://hdl.handle.net/10722/284088 |
ISSN | 2023 Impact Factor: 3.4 2023 SCImago Journal Rankings: 1.255 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Ko, KL | - |
dc.contributor.author | To, WP | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2020-07-20T05:55:59Z | - |
dc.date.available | 2020-07-20T05:55:59Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Gut and Liver, 2020, Epub 2020-05-29 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | http://hdl.handle.net/10722/284088 | - |
dc.description.abstract | Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of HBcrAg in entecavir (ETV)-treated CHB patients with subsequent HCC development. We identified HCC cases diagnosed at ≥1 year after ETV initiation. CHB patients without HCC (matched for age, sex, cirrhosis status, baseline hepatitis B virus (HBV) DNA level, and ETV treatment duration) were identified as controls at an HCC:non-HCC ratio of 1:2. Serum samples were retrieved at baseline (ETV initiation) and at 3 and 5 years of ETV therapy for HBcrAg measurement (log IU/mL). In total, 180 patients (60 HCC patients matched with 120 CHB patients without HCC; median age, 56.5 years; 80.6% male; baseline HBV DNA, 5.9 log IU/mL; median follow-up, 6.8 years) were recruited. The median time from ETV initiation to HCC development was 3.2 years. HBcrAg levels were higher in HCC cases than in controls at all three time points: 5.69 log IU/mL versus 5.02 log IU/mL (p=0.025), 4.23 log IU/mL versus 3.36 log IU/mL (p=0.007), and 3.86 log IU/mL vs 3.36 log IU/mL (p=0.009), respectively. ETV led to similar rates of decline in HBcrAg from baseline to 3 years in both groups (0.34 log IU/mL/year vs 0.39 log IU/mL/year, p=0.774), although the decline from 3 to 5 years was slower in the non-HCC group (0.05 log IU/mL/year) than in the HCC group (0.09 log IU/mL/year, p=0.055). ETV time-dependently reduced HBcrAg in HCC and non-HCC patients. HBcrAg interpretation should consider the antiviral treatment duration. | - |
dc.language | eng | - |
dc.publisher | Gut and Liver, Editorial Office. The Journal's web site is located at http://www.gutnliver.org/ | - |
dc.relation.ispartof | Gut and Liver | - |
dc.rights | Gut and Liver. Copyright © Gut and Liver, Editorial Office. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Entecavir | - |
dc.subject | Hepatocellular carcinoma | - |
dc.subject | Hepatitis B core-related antigen | - |
dc.subject | Chronic hepatitis B | - |
dc.title | Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.identifier.email | Mak, LY: lungyi@hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Mak, LY=rp02668 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.5009/gnl19434 | - |
dc.identifier.pmid | 32457279 | - |
dc.identifier.scopus | eid_2-s2.0-85090913433 | - |
dc.identifier.hkuros | 310916 | - |
dc.identifier.volume | Epub 2020-05-29 | - |
dc.identifier.isi | WOS:000569359000018 | - |
dc.publisher.place | Korea, Republic of | - |
dc.identifier.issnl | 1976-2283 | - |